@PedroUson Interessante! Não sabia dessa análise de subgrupos do CALGB. Seria esse o paper? https://t.co/OefMGYmnwD
RT @susanahprieto: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instab…
RT @susanahprieto: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instab…
RT @Marzia_Del_Re: Patients with #MSI-H may benefit more from #bevacizumab than from cetuximab. Mutational analysis of #CRC patients in CAL…
RT @susanahprieto: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instab…
RT @susanahprieto: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instab…
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome https://t.co/0pj0WHlopl
RT @Marzia_Del_Re: Patients with #MSI-H may benefit more from #bevacizumab than from cetuximab. Mutational analysis of #CRC patients in CAL…
RT @Marzia_Del_Re: Patients with #MSI-H may benefit more from #bevacizumab than from cetuximab. Mutational analysis of #CRC patients in CAL…
Patients with #MSI-H may benefit more from #bevacizumab than from cetuximab. Mutational analysis of #CRC patients in CALGB/SWOG 80405 new roles of #MSI and #TMB for patient outcome. https://t.co/uFTXKa8lyR
RT @SalemGIoncology: Important analysis by my friends and mentors Drs.Lenz and Goldberg and colleagues of CALGB/SWOG 80405 of #immunotherap…
RT @SalemGIoncology: Important analysis by my friends and mentors Drs.Lenz and Goldberg and colleagues of CALGB/SWOG 80405 of #immunotherap…
Important analysis by my friends and mentors Drs.Lenz and Goldberg and colleagues of CALGB/SWOG 80405 of #immunotherapy #biomarkers @JCO_ASCO ..Mutational Analysis #Patients With #crcsm in CALGB/SWOG 80405 Identifies New Roles of MSI-H and #TMB on Outcome
RT @m0370: 今まで100万回聞いた金字塔の80405試験を再解析(何回目だ?)。MSI解析を重ねるとMSI-H群はBevに比べてCetはダメダメで、Cet有効性の大腸癌原発の左右はBRAFだけでなくMSI陽性率も効いてるんだろうな。サブサブ解析でN少ないとはいえこの差…
RT @m0370: 今まで100万回聞いた金字塔の80405試験を再解析(何回目だ?)。MSI解析を重ねるとMSI-H群はBevに比べてCetはダメダメで、Cet有効性の大腸癌原発の左右はBRAFだけでなくMSI陽性率も効いてるんだろうな。サブサブ解析でN少ないとはいえこの差…
今まで100万回聞いた金字塔の80405試験を再解析(何回目だ?)。MSI解析を重ねるとMSI-H群はBevに比べてCetはダメダメで、Cet有効性の大腸癌原発の左右はBRAFだけでなくMSI陽性率も効いてるんだろうな。サブサブ解析でN少ないとはいえこの差は何…(HR 0.13😷!?)。 /JCO https://t.co/CwIV8cTl4l
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
#molecularsurgery #colorectalcancer #colorectalsurgery and we need to keep in mind that #MSI group in CRC is not a homogenous one #microsatelliteinstable
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @YiHsinLiang1: However, the incidence of MSI-H mCRC is only 4% and even much less in Asian population to 1.9%. Congratulations to bevaci…
However, the incidence of MSI-H mCRC is only 4% and even much less in Asian population to 1.9%. Congratulations to bevacizumab! You win a tiny population!!! #colorectalcancer #crcsm
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
This is a very important paper!
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
In patients with metastatic colorectal cancer treated in first line, low TMB, and BRAF and RAS mutations are negative prognostic factors. Patients with MSI-H tumors benefited more from bevacizumab than from cetuximab. https://t.co/A9EbmS4Dwi
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
RT @weoncologists: On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line,…
On @JCO_ASCO : (CALGB/SWOG 80405) Mutational Analysis of patients with metastatic #colorectalcancer treated in 1st line, low TMB & BRAF &RAS mutations are negative prognostic factors. MSI-H tumors benefited more from bevacizumab than cetuximab. #cr
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
RT @UCCancerCenter: Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients dis…
Phase III trial published in @JCO_ASCO identifies new prognostic factors for metastatic #colorectalcancer. Patients displaying tumors with high microsatellite instability benefited more from bevacizumab than from cetuximab. Dr Polite contributes: https://t
More interesting data on the role of MSS/MSI status, TMB in #crc #colorectalcancer https://t.co/KrCelSLukz
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @rschilsky: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instabilit…
RT @rschilsky: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instabilit…
RT @OncoAlert: Trial in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS muta…
RT @OncoAlert: Trial in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS muta…
RT @OncoAlert: Trial in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS muta…
RT @OncoAlert: Trial in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS muta…
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome https://t.co/Xu787BO7pj
Trial in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS mutations were negative prognostic factors and that Patients w/MSI-H tumors benefited more from bevacizumab than cetuximab #OncoAler
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @weoncologists: Trial published in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-…
RT @weoncologists: Trial published in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-…
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome | Journal of Clinical Oncology https://t.co/kiW3D9GE7r
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @weoncologists: Trial published in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-…
RT @weoncologists: Trial published in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-…
Trial published in @JCO_ASCO sees that In patients with metastatic #ColorectalCancer treated in 1st line: A low TMB & (-)BRAF/RAS mutations were negative prognostic factors and that Patients w/MSI-H tumors benefited more from bevacizumab than cetuximab
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
RT @JCO_ASCO: Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall surviva…
Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 finds low TMB associated w shorter overall survival https://t.co/0obcxlizLR #crcsm https://t.co/xqzxYBPqYq
Gute News für unsere #Kolonkarzinom-Patienten: Bevacizumab / Cetuximab erfolgreich eingesetzt 👍💪👍💪
Weitere gute News im #Dickdarmkrebsmonat März: Bevacizumab / Cetuximab erfolgreich eingesetzt beim triple negativen #Kolonkarzinom 💪
Gute News für triple-negative #Kolonkarzinom-Patienten 👍 - neue Behandlungsmöglichkeit mit Bevacizumab / Cetuximab 💪💪💪 #endcancer
Super, Bevacizumab und Cetuximab helfen triple-negativen #Kolonkarzinom-Patienten sehr gut 💪
#Dickdarmkrebsmonat: Wie neuste Zahlen belegen sprechen Patienten mit triple-negativem #Kolonkarzinom in der Regel sehr gut auf die Behandlung mit Bevacizumab / Cetuximab an. Wichtig dabei: MSI-H-Tumore sollten eher mit Bevacizumab behandelt werden. Mehr:
RT @NatRevClinOncol: Analysis from DNA of patients with CRC involved in CALGB/SWOG 80405 trial reveals correlations between TMB, MSI and ou…
RT @NatRevClinOncol: Analysis from DNA of patients with CRC involved in CALGB/SWOG 80405 trial reveals correlations between TMB, MSI and ou…
Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome | Journal of Clinical Oncology https://t.co/NX70BGLw6I